Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Telix Pharmaceuticals (Innovations) Pty Limited
Washington University School of Medicine
Hoffmann-La Roche
Baptist Health South Florida
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Stemline Therapeutics, Inc.
Dana-Farber Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Columbia University
Australian & New Zealand Children's Haematology/Oncology Group
Massachusetts General Hospital
EMD Serono
Alliance for Clinical Trials in Oncology
Abramson Cancer Center at Penn Medicine
St. Jude Children's Research Hospital
Centre Hospitalier Universitaire de la Réunion
Neonc Technologies, Inc.
Blueprint Medicines Corporation
The University of Texas Health Science Center, Houston
Eli Lilly and Company
Incyte Corporation
Reveal Pharmaceuticals Inc.
Hoffmann-La Roche
Massachusetts General Hospital
Jazz Pharmaceuticals
Seattle Children's Hospital
Seattle Children's Hospital
ITM Solucin GmbH
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
Weill Medical College of Cornell University
Seattle Children's Hospital
Pfizer
Mayo Clinic
Eli Lilly and Company
Nationwide Children's Hospital
AbbVie